Testing a new chikungunya vaccine in healthy volunteers
Part of Infections clinical trials.
This study tests a new vaccine to see if it's safe and helps protect against chikungunya virus (a mosquito-borne illness causing fever and joint pain). It's for healthy adults ages 18 to 60 who haven't recently traveled to areas with similar viruses or received certain other vaccines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 60 years old and in good general health
- Agree to use effective birth control (if applicable) during the study and for a period of time after
- Not have had chikungunya, Zika, dengue, or similar mosquito-borne diseases in the past 90 days
- Not have traveled to areas with these viruses in the past 90 days
- Not have received a chikungunya or related vaccine in the past 90 days
- Be willing to avoid other vaccines and certain medications during the study period
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental chikungunya vaccine (made from a virus-like particle) to see if it prevents the disease. It is for healthy teens and adults who have not had chikungunya before.
This study tests a vaccine for chikungunya virus in children aged 1 to 12. It aims to see if the vaccine is safe and helps the body build protection against the virus.
This trial tests whether giving two vaccines (one for dengue, one for chikungunya) at the same time is as safe and effective as giving them separately. It may be a good option if you haven't been exposed to these viruses and are generally healthy.
This study looks at how well the VLA1553 vaccine prevents chikungunya disease in parts of Brazil where the vaccine is being offered as part of a pilot program. If you live in one of those areas and have had symptoms that might be chikungunya, this study will use your health records and blood tests to check how effective the vaccine is.
This study follows pregnant women who received the VLA1553 vaccine (for chikungunya) to see how it affects them and their babies. It compares them to pregnant women who received a different vaccine approved during pregnancy.
This trial tests a new treatment (PC-CHIK-V) for newborns whose mothers had chikungunya around the time of birth. The goal is to see if the treatment can prevent or reduce the infection in babies. Babies who are not treated will also be followed for comparison.
Hear when a new Chikungunya trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.